The finding that the transmembrane tyrosine kinase HER2 is overexpressed in 15–25% of human breast tumors together with correlation with aggressive tumor growth and poor prognosis [1] fostered the development of agents to target that protein with therapeutic purposes [2]. The gene discussed is ERBB2; the disease is neoplasm.